Literature DB >> 2545766

Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism.

B Ambrosi1, D Bochicchio, R Ferrario, P Colombo, G Faglia.   

Abstract

In the present work the possible use of loperamide, an opiate agonist, in the dynamic evaluation of patients with suspected hypercortisolism was investigated. The effects of loperamide on plasma ACTH and cortisol levels were evaluated in normal subjects and in 58 patients with suspected Cushing's syndrome. The results were compared to those obtained after the overnight dexamethasone suppression test. In normal subjects plasma ACTH and cortisol levels were significantly (p less than 0.005) suppressed by both loperamide (16 mg po) and dexamethasone (1 mg po). In 17 patients, in whom the diagnosis of Cushing's syndrome was confirmed by subsequent investigations, neither loperamide or dexamethasone inhibited cortisol (from a baseline of 606 +/- 55 nmol/L) to a nadir of 502 +/- 43 nmol/L and 539 +/- 50 nmol/L, respectively) and ACTH concentration (from a basal level of 70.1 +/- 11.8 pg/ml to a nadir of 46.0 +/- 8.6 pg/ml and 54.3 +/- 7.5 pg/ml, respectively). In 34 patients, in whom the suspect of hypercortisolism was ruled out, either loperamide or dexamethasone suppressed the pituitary-adrenal axis: cortisol and ACTH levels significantly fell from 417 +/- 24 nmol/L and 28.3 +/- 3.5 pg/ml to 60 +/- 6 nmol/L and 14.4 +/- 1.4 pg/ml after loperamide and to 26 +/- 4 nmol and 16.4 +/- 1.7 pg/ml after dexamethasone. In 7 patients discordant responses were observed. In 3 patients treated with antiepileptic drugs ACTH and cortisol levels were inhibited by loperamide, but not by dexamethasone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545766     DOI: 10.1007/BF03349913

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

1.  "Normal suppression" to dexamethasone in Cushing's disease: an expression of decreased metabolic clearance for dexamethasone.

Authors:  J F Caro; A W Meikle; J H Check; S N Cohen
Journal:  J Clin Endocrinol Metab       Date:  1978-09       Impact factor: 5.958

2.  Effects of high-dose and low-dose naloxone on plasma ACTH in patients with ACTH hypersecretion.

Authors:  U Deuss; B Allolio; D Kaulen; H Fischer; W Winkelmann
Journal:  Clin Endocrinol (Oxf)       Date:  1985-03       Impact factor: 3.478

3.  FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease.

Authors:  B Allolio; U Deuss; D Kaulen; U Leonhardt; D Kallabis; E Hamel; W Winkelmann
Journal:  J Clin Endocrinol Metab       Date:  1986-12       Impact factor: 5.958

4.  Effect of naloxone on pituitary hypersecretory syndromes.

Authors:  G Tolis; L Jukier; M Wiesen; D T Krieger
Journal:  J Clin Endocrinol Metab       Date:  1982-04       Impact factor: 5.958

5.  Loperamide, an opiate analogue, inhibits plasma ACTH levels in patients with Addison's disease.

Authors:  B Ambrosi; D Bochicchio; G Faglia
Journal:  Clin Endocrinol (Oxf)       Date:  1986-05       Impact factor: 3.478

6.  Loperamide binding to opiate receptor sites of brain and myenteric plexus.

Authors:  C R Mackerer; G A Clay; E Z Dajani
Journal:  J Pharmacol Exp Ther       Date:  1976-10       Impact factor: 4.030

7.  Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion.

Authors:  B Allolio; W Winkelmann; F X Hipp; D Kaulen; R Mies
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

8.  The effects of a met-enkephalin analogue on ACTH, beta-LPH, beta-endorphin and MET-enkephalin in patients with adrenocortical disease.

Authors:  R C Gaillard; A Grossman; R Smith; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1981-05       Impact factor: 3.478

9.  The effect of naloxone on ATCH and beta-endorphin in patients with Cushing's disease.

Authors:  B Baranowska; W Dorobek; W Misiorowski; W Jeske; M H Abdel-Fattah
Journal:  Acta Endocrinol (Copenh)       Date:  1985-10

10.  Endocrine effect of a methionine-enkephalin derivative (FK 33-824) in man.

Authors:  E del Pozo; B von Graffenried; J Brownell; F Derrer; P Marbach
Journal:  Horm Res       Date:  1980
View more
  5 in total

1.  The silent corticotropinoma: is clinical diagnosis possible?

Authors:  B Ambrosi; P Colombo; D Bochicchio; M Bassetti; B Masini; G Faglia
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

2.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

3.  Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions.

Authors:  G P Bernini; G F Argenio; F Cerri; F Franchi
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

4.  Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project.

Authors:  William R Lovallo; Andrea C King; Noha H Farag; Kristen H Sorocco; Andrew J Cohoon; Andrea S Vincent
Journal:  Psychoneuroendocrinology       Date:  2012-05-08       Impact factor: 4.905

5.  Early life adversity diminishes the cortisol response to opioid blockade in women: Studies from the Family Health Patterns project.

Authors:  William R Lovallo; Ashley Acheson; Andrea S Vincent; Kristen H Sorocco; Andrew J Cohoon
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.